Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study

Abdurehman Seid Mohammed; Mustofa Hassen Yesuf; Chekole Sileshi Menbere; Getachew Mekete Diress

doi:doi:10.11648/j.ajcem.20241205.12

Research Article |

| Peer-Reviewed

Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study

Abdurehman Seid Mohammed^*

, Mustofa Hassen Yesuf

, Chekole Sileshi Menbere

, Getachew Mekete Diress

Published in American Journal of Clinical and Experimental Medicine (Volume 12, Issue 5)

Received: 10 November 2024 Accepted: 23 November 2024 Published: 12 December 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: A synthetic oxazolidinone antimicrobial medication called Linezolid is used to treat patients who are resistant to multiple drugs. Few studies have been done regarding the effectiveness of Linezolid-containing regimens in both developing and developed nations. This study aimed to determine the Efficacy and determinant factors of linezolid-containing regimens in the treatment of DR - TB Patients. Methods: An institution-based cross-sectional study design was conducted using SPSS version 26, and multivariable binary logistic regression analysis was used. Result: out of 345 patients that visited the outpatient clinic, 205 (59.4%) were males, and 126(36.5%) were between 30-39 years. MDR TB Patients' linezolid-containing regimen treatment efficacy success rate is 280(81.2%). MDR TB Patient Previously Treated TB by First Line Drug [AOR= 5.823(3.761-7.341)]. MDR TB Patient Previously Treated TB by First Line and treatment completed [AOR=2.351(1.34-3.214))], the adverse effect [AOR 0.842(0.674-2.431], tolerability of linezolid [AOR =2.543(2.41-4.532)] was significantly associated with linezolid containing regimen treatment efficacy rate. Conclusion: Linezolid-containing regimens have good efficacy and good treatment outcomes for DR-TB patients. The findings showed that Linezolid is a good choice for treating DR-TB, although patients ought to be monitored closely for the incidence of adverse effects.

Published in	American Journal of Clinical and Experimental Medicine (Volume 12, Issue 5)
DOI	10.11648/j.ajcem.20241205.12
Page(s)	74-86
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Multidrug Resistance, TB, linezolid, Efficacy, Tolerability Safety, Addis Ababa, Ethiopia

References

[1]	Organization, W. H., Contributions of WHO to South Africa’s health agenda: evaluation of the Country Cooperation Strategy 2016-2020. 2022.
[2]	Organization, W. H., WHO country stories: delivering for all. 2023: World Health Organization.
[3]	Bagcchi, S., WHO's global tuberculosis report 2022. The Lancet Microbe, 2023. 4(1): p. e20.
[4]	Eshetie, S., et al., Multidrug-resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infectious Diseases, 2017. 17: p. 1-12.
[5]	Migliori, G. B., et al., Review of multidrug‐resistant and extensively drug‐resistant TB: global perspectives with a focus on sub‐Saharan Africa. Tropical Medicine & International Health, 2010. 15(9): p. 1052-1066.
[6]	Seid, M. A., et al., Drug-susceptible tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a systematic review and meta-analysis. BMJ Open, 2018. 8(9): p. e022111.
[7]	Perry, C. M., and B. Jarvis, Linezolid: a review of its use in the management of serious gram-positive infections. Drugs, 2001. 61: p. 525-551.
[8]	Azzouz, A. and C. V. Preuss, Linezolid, in StatPearls [Internet]. 2024, StatPearls Publishing.
[9]	Babcock, H. M. and V. Fraser, Clinical experience with linezolid: a case series of 53 patients. Infectious Diseases in Clinical Practice, 2002. 11(4): p. 198-204.
[10]	Bloom, B. R., A half-century of research on tuberculosis: Successes and challenges. Journal of Experimental Medicine, 2023. 220(9): p. e20230859.
[11]	Bloom, B. R. and J. D. McKinney, The death and resurrection of tuberculosis. Nature medicine, 1999. 5(8): p. 872-874.
[12]	Vinh, D. C. and J. M. Embil, Device-related infections: a review. Journal of long-term effects of medical implants, 2005. 15(5).
[13]	Vinh, D. C. and E. Rubinstein, Linezolid: a review of safety and tolerability. Journal of Infection, 2009. 59: p. S59-S74.
[14]	Clemett, D. and A. Markham, Linezolid. Drugs, 2000. 59: p. 815-827.
[15]	Mala, G., et al., Why tuberculosis service providers do not follow treatment guideline in E Ethiopia: a qualitative study. Journal of evaluation in clinical practice, 2014. 20(1): p. 88-93.
[16]	Hamel, E., Perivascular nerves and the regulation of cerebrovascular tone. Journal of Applied Physiology, 2006. 100(3): p. 1059-1064.
[17]	Ma, A., et al., Clinical efficacy and safety of linezolid in intensive care unit patients. Journal of Intensive Medicine, 2023. 3(1): p. 65-72.
[18]	Agyeman, A. A. and R. Ofori-Asenso, Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Annals of clinical microbiology and antimicrobials, 2016. 15: p. 1-17.
[19]	Wasserman, S., et al., Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2022. 77(4): p. 1146-1154.
[20]	Kizito, E., et al., Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda-a case-control study. BMC Infectious Diseases, 2021. 21: p. 1-7.
[21]	Zegeye, A., et al., Prevalence and determinants of anti-tuberculosis treatment non-adherence in Ethiopia: A systematic review and meta-analysis. PloS one, 2019. 14(1): p. e0210422.
[22]	Abseno, M., THE PREVALENCE OF TUBERCULOSIS AMONG ADDIS ABABA CITY BUS DRIVERS AND CASH COLLECTORS. 2004.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mohammed, A. S., Yesuf, M. H., Menbere, C. S., Diress, G. M. (2024). Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study. American Journal of Clinical and Experimental Medicine, 12(5), 74-86. https://doi.org/10.11648/j.ajcem.20241205.12

Copy | Download

ACS Style

Mohammed, A. S.; Yesuf, M. H.; Menbere, C. S.; Diress, G. M. Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study. Am. J. Clin. Exp. Med. 2024, 12(5), 74-86. doi: 10.11648/j.ajcem.20241205.12

Copy | Download

AMA Style

Mohammed AS, Yesuf MH, Menbere CS, Diress GM. Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study. Am J Clin Exp Med. 2024;12(5):74-86. doi: 10.11648/j.ajcem.20241205.12

Copy | Download

@article{10.11648/j.ajcem.20241205.12,
  author = {Abdurehman Seid Mohammed and Mustofa Hassen Yesuf and Chekole Sileshi Menbere and Getachew Mekete Diress},
  title = {Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study
},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {12},
  number = {5},
  pages = {74-86},
  doi = {10.11648/j.ajcem.20241205.12},
  url = {https://doi.org/10.11648/j.ajcem.20241205.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20241205.12},
  abstract = {Background: A synthetic oxazolidinone antimicrobial medication called Linezolid is used to treat patients who are resistant to multiple drugs. Few studies have been done regarding the effectiveness of Linezolid-containing regimens in both developing and developed nations. This study aimed to determine the Efficacy and determinant factors of linezolid-containing regimens in the treatment of DR - TB Patients. Methods: An institution-based cross-sectional study design was conducted using SPSS version 26, and multivariable binary logistic regression analysis was used. Result: out of 345 patients that visited the outpatient clinic, 205 (59.4%) were males, and 126(36.5%) were between 30-39 years. MDR TB Patients' linezolid-containing regimen treatment efficacy success rate is 280(81.2%). MDR TB Patient Previously Treated TB by First Line Drug [AOR= 5.823(3.761-7.341)]. MDR TB Patient Previously Treated TB by First Line and treatment completed [AOR=2.351(1.34-3.214))], the adverse effect [AOR 0.842(0.674-2.431], tolerability of linezolid [AOR =2.543(2.41-4.532)] was significantly associated with linezolid containing regimen treatment efficacy rate. Conclusion: Linezolid-containing regimens have good efficacy and good treatment outcomes for DR-TB patients. The findings showed that Linezolid is a good choice for treating DR-TB, although patients ought to be monitored closely for the incidence of adverse effects.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study

AU  - Abdurehman Seid Mohammed
AU  - Mustofa Hassen Yesuf
AU  - Chekole Sileshi Menbere
AU  - Getachew Mekete Diress
Y1  - 2024/12/12
PY  - 2024
N1  - https://doi.org/10.11648/j.ajcem.20241205.12
DO  - 10.11648/j.ajcem.20241205.12
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 74
EP  - 86
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20241205.12
AB  - Background: A synthetic oxazolidinone antimicrobial medication called Linezolid is used to treat patients who are resistant to multiple drugs. Few studies have been done regarding the effectiveness of Linezolid-containing regimens in both developing and developed nations. This study aimed to determine the Efficacy and determinant factors of linezolid-containing regimens in the treatment of DR - TB Patients. Methods: An institution-based cross-sectional study design was conducted using SPSS version 26, and multivariable binary logistic regression analysis was used. Result: out of 345 patients that visited the outpatient clinic, 205 (59.4%) were males, and 126(36.5%) were between 30-39 years. MDR TB Patients' linezolid-containing regimen treatment efficacy success rate is 280(81.2%). MDR TB Patient Previously Treated TB by First Line Drug [AOR= 5.823(3.761-7.341)]. MDR TB Patient Previously Treated TB by First Line and treatment completed [AOR=2.351(1.34-3.214))], the adverse effect [AOR 0.842(0.674-2.431], tolerability of linezolid [AOR =2.543(2.41-4.532)] was significantly associated with linezolid containing regimen treatment efficacy rate. Conclusion: Linezolid-containing regimens have good efficacy and good treatment outcomes for DR-TB patients. The findings showed that Linezolid is a good choice for treating DR-TB, although patients ought to be monitored closely for the incidence of adverse effects.

VL  - 12
IS  - 5
ER  -

Copy | Download

Author Information

Abdurehman Seid Mohammed

Department of Public Health, Saint Peter Specialized Hospital, Addis Ababa, Ethiopia

Contact Email

http://orcid.org/0009-0003-2335-1508
Mustofa Hassen Yesuf

Department of Internal Medicine: Saint Peter Specialized Hospital, Addis Ababa, Ethiopia

Contact Email

http://orcid.org/0009-0004-6191-4102
Chekole Sileshi Menbere

Department of Public Health, Saint Peter Specialized Hospital, Addis Ababa, Ethiopia

Contact Email

http://orcid.org/0009-0003-3574-8289
Getachew Mekete Diress

Department of Anaesthesia, College of Health Sciences, School of Medicine, Debre Tabor University, Debre Tabor, Ethiopia

Contact Email

http://orcid.org/0009-0006-1463-3222

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mohammed, A. S., Yesuf, M. H., Menbere, C. S., Diress, G. M. (2024). Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study. American Journal of Clinical and Experimental Medicine, 12(5), 74-86. https://doi.org/10.11648/j.ajcem.20241205.12

Copy | Download

ACS Style

Mohammed, A. S.; Yesuf, M. H.; Menbere, C. S.; Diress, G. M. Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study. Am. J. Clin. Exp. Med. 2024, 12(5), 74-86. doi: 10.11648/j.ajcem.20241205.12

Copy | Download

AMA Style

Mohammed AS, Yesuf MH, Menbere CS, Diress GM. Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study. Am J Clin Exp Med. 2024;12(5):74-86. doi: 10.11648/j.ajcem.20241205.12

Copy | Download

@article{10.11648/j.ajcem.20241205.12,
  author = {Abdurehman Seid Mohammed and Mustofa Hassen Yesuf and Chekole Sileshi Menbere and Getachew Mekete Diress},
  title = {Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study
},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {12},
  number = {5},
  pages = {74-86},
  doi = {10.11648/j.ajcem.20241205.12},
  url = {https://doi.org/10.11648/j.ajcem.20241205.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20241205.12},
  abstract = {Background: A synthetic oxazolidinone antimicrobial medication called Linezolid is used to treat patients who are resistant to multiple drugs. Few studies have been done regarding the effectiveness of Linezolid-containing regimens in both developing and developed nations. This study aimed to determine the Efficacy and determinant factors of linezolid-containing regimens in the treatment of DR - TB Patients. Methods: An institution-based cross-sectional study design was conducted using SPSS version 26, and multivariable binary logistic regression analysis was used. Result: out of 345 patients that visited the outpatient clinic, 205 (59.4%) were males, and 126(36.5%) were between 30-39 years. MDR TB Patients' linezolid-containing regimen treatment efficacy success rate is 280(81.2%). MDR TB Patient Previously Treated TB by First Line Drug [AOR= 5.823(3.761-7.341)]. MDR TB Patient Previously Treated TB by First Line and treatment completed [AOR=2.351(1.34-3.214))], the adverse effect [AOR 0.842(0.674-2.431], tolerability of linezolid [AOR =2.543(2.41-4.532)] was significantly associated with linezolid containing regimen treatment efficacy rate. Conclusion: Linezolid-containing regimens have good efficacy and good treatment outcomes for DR-TB patients. The findings showed that Linezolid is a good choice for treating DR-TB, although patients ought to be monitored closely for the incidence of adverse effects.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study

AU  - Abdurehman Seid Mohammed
AU  - Mustofa Hassen Yesuf
AU  - Chekole Sileshi Menbere
AU  - Getachew Mekete Diress
Y1  - 2024/12/12
PY  - 2024
N1  - https://doi.org/10.11648/j.ajcem.20241205.12
DO  - 10.11648/j.ajcem.20241205.12
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 74
EP  - 86
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20241205.12
AB  - Background: A synthetic oxazolidinone antimicrobial medication called Linezolid is used to treat patients who are resistant to multiple drugs. Few studies have been done regarding the effectiveness of Linezolid-containing regimens in both developing and developed nations. This study aimed to determine the Efficacy and determinant factors of linezolid-containing regimens in the treatment of DR - TB Patients. Methods: An institution-based cross-sectional study design was conducted using SPSS version 26, and multivariable binary logistic regression analysis was used. Result: out of 345 patients that visited the outpatient clinic, 205 (59.4%) were males, and 126(36.5%) were between 30-39 years. MDR TB Patients' linezolid-containing regimen treatment efficacy success rate is 280(81.2%). MDR TB Patient Previously Treated TB by First Line Drug [AOR= 5.823(3.761-7.341)]. MDR TB Patient Previously Treated TB by First Line and treatment completed [AOR=2.351(1.34-3.214))], the adverse effect [AOR 0.842(0.674-2.431], tolerability of linezolid [AOR =2.543(2.41-4.532)] was significantly associated with linezolid containing regimen treatment efficacy rate. Conclusion: Linezolid-containing regimens have good efficacy and good treatment outcomes for DR-TB patients. The findings showed that Linezolid is a good choice for treating DR-TB, although patients ought to be monitored closely for the incidence of adverse effects.

VL  - 12
IS  - 5
ER  -

Copy | Download